Align Technology, Inc. (ALGN) Stock: Price, Forecast & Analyst Target
Align Technology, Inc. (ALGN) — MoonshotScore 83/100 (Exceptional band), calculated Nov 18, 2026. Price $163.96 (+0.31%), as of the Nov 18, 2026 trading session; market cap $11.6B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 10.13× (cash as of Sep 30, 2026) · expected results Feb 3, 2027
Align Technology, Inc. · ALGN · NASDAQ · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Align Technology sells Invisalign treatment products and iTero scanning hardware, software and services to dental professionals, with clear aligners supplying the dominant share of revenue. Its economics depend more on clinician-started treatment cases and the price earned per case than on scanner shipments alone. Recent sales progress matters only if it translates into firmer profit while lower selling prices and restructuring costs press margins.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Align Technology (ALGN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and a strong balance sheet, though growth is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.
- quarterly revenue $996M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 5 of the last 8 reports
- expected results Feb 3, 2027
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 80 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $163.96 | |
| Change on the day | +0.31% | |
| 52-week range | $130.23–$200.44 | |
| Market capitalisation | $11.6B | — |
| Price / earnings (trailing) | 23.76 | |
| Shares traded on the day | 892.0K | |
| Beta (volatility vs the S&P 500) | 1.74 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For fiscal 2026, we expect 2026 worldwide revenue to be approximately $4.11 billion to $4.13 billion.
John Morici · Statement from
We continue to expect 2026 Clear Aligner volume and revenue growth to be up approximately 5% to 6% year-over-year.
John Morici · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Align Technology (ALGN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Align Technology (ALGN), and what does it report?
Short answer · as of
Align is not chiefly a dental-equipment vendor.
Research dated 2026-09-13.
Invisalign offerings span comprehensive and limited treatments, retainers, training and clinical accessories, while iTero combines scanners with diagnostic, treatment-planning and restorative applications. Reported revenue therefore blends case-based treatment products with scanner hardware, software and related services, although clear aligners remain the much larger business.
What do the latest results show for Align Technology (ALGN)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $996M.
Research dated 2026-09-13.
Revenue edged higher in the latest period, yet gross profit, operating income, net income and diluted earnings weakened from the preceding period. The longer record tells a similar story: annual sales have advanced gradually while net profit has remained below its earlier peak, even as reported revenue and earnings have generally cleared recent consensus expectations. Management expects further near-term margin pressure from lower average selling prices, accelerated depreciation, restructuring and related charges; that outlook describes the coming pressure rather than explaining the latest result.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.01B Sep 30, 2026
- Latest quarter · R&D
- $93.87M Sep 30, 2026
- Latest quarter · SG&A
- $410.55M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $169.16M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $1.01B | $93.87M | $410.55M | $169.16M |
| Jun 30, 2026 | $1.06B | $102.03M | $462.67M | $123.30M |
| Mar 31, 2026 | $1.04B | $98.66M | $465.34M | $172.67M |
| Dec 31, 2025 | $1.05B | $83.04M | $440.74M | $159.59M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.01B Oct 28, 2026
- Latest report · revenue estimate
- $1.00B Oct 28, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 28, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 28, 2026 | $1.01B | $1.00B | $2.8000 | $2.7700 |
| Jul 29, 2026 | $1.06B | $1.05B | $2.6400 | $2.6200 |
| Apr 29, 2026 | $1.04B | $1.02B | $2.5800 | $2.3000 |
| Feb 4, 2026 | $1.05B | $1.03B | $3.2900 | $2.9900 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $996M | $57M | $0.78 (diluted) |
| Q4 FY2025 | $1.05B | $136M | $1.89 (diluted) |
| Q1 FY2026 | $1.04B | $113M | $1.57 (diluted) |
| Q2 FY2026 | $1.06B | $108M | $1.52 (diluted) |
What are the financial strengths and risks for Align Technology (ALGN)?
Short answer
Cash and short-term investments were $1.14B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $182.92M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments materially exceed total debt, liquidity ratios remain above parity, and operating cash flow has stayed positive throughout the reported series. Cash also recovered after an earlier decline, leaving Align with meaningful capacity to absorb restructuring costs and continue product development. The operating risk sits in clear-aligner economics: because that segment generates most revenue, sustained price pressure would weigh on gross profit unless treatment demand or product mix compensates.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $182.92M Sep 30, 2026
- Previous quarter · operating cash flow
- $192.76M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $182.92M | −$45.03M |
| Jun 30, 2026 | $192.76M | −$35.66M |
| Mar 31, 2026 | $151.04M | −$30.78M |
| Dec 31, 2025 | $223.18M | −$35.92M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Align Technology (ALGN)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-13.
At the coming release, compare revenue with the recent run rate and the expected sequential step-down, then separate underlying profitability from the charges management has identified. Management expects reported margins to absorb restructuring and accelerated depreciation while presenting materially stronger adjusted-margin expectations, making the gap between those measures especially important. Cash conversion is another useful check: operating cash flow recovered from its earlier trough and cash increased, so a reversal alongside weaker profit would alter the financial picture.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect 2026 Systems and Services revenue to be $715 million to $725 million.
John Morici ·
We expect 2026 GAAP operating margin to be approximately 16.2%, up approximately 2.7 points year-over-year.
John Morici ·
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 5, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Align Technology compare with its peers?
Short answer
Align Technology's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a pure scanner vendor, Align has a case-based treatment engine whose revenue depends on clinicians initiating Invisalign therapies and selecting among treatment packages. Compared with a pure orthodontic-product company, iTero adds scanner hardware, clinical software, digital records and restorative workflows. That pairing broadens the clinician relationship, but clear aligners remain dominant enough that scanner success alone cannot determine companywide performance.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $320.50 Nov 18, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| Align Technology (ALGN) — this page | $163.96 | $11.6B | 83 |
| $122.86 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $85.93 Nov 18, 2026 | $5.15B | 81 5-pillar Nov 18, 2026 | |
| $141.67 Nov 18, 2026 | $8.98B | 77 5-pillar Nov 18, 2026 | |
| $182.98 Nov 18, 2026 | $10.7B | 74 5-pillar Nov 18, 2026 | |
| $172.67 Nov 18, 2026 | $11.0B | 71 5-pillar Nov 18, 2026 | |
| $15.37 Nov 18, 2026 | $10.4B | 71 5-pillar Nov 18, 2026 | |
| $165.85 Nov 18, 2026 | $6.58B | 61 5-pillar Nov 18, 2026 | |
| $61.43 Nov 18, 2026 | $11.9B | 58 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $162.00 – $215.00
- Consensus target
- $190.00
- Median target
- $189.00
Consensus record · Captured .
Measured against a quoted price of $163.96 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 641 Period end Sep 30, 2026
- Previous quarter · holders
- 712 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 5,527,912 |
| Blackrock, INC. | 4,482,335 |
| Capital International Investors | 4,479,009 |
| Vanguard Capital Management LLC | 4,365,915 |
| Capital World Investors | 3,632,336 |
Tracked investors
Which of the 16 named investors we follow held ALGN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.07% | $15.87M | Added +32.5% shares |
| ARK Invest | Cathie Wood | Q3 2026 | 0.00% | $794,628 | Added +3.9% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Align Technology (ALGN)?
ALGN Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Invisalign case activity matter more than iTero scanner sales for Align Technology?
Clear aligners contribute most of Align’s segment revenue, so treatment starts, package selection and case pricing carry greater weight in companywide results. iTero remains strategically relevant because its scanning and clinical applications sit inside the dental workflow.
Why can lower Invisalign selling prices hurt Align Technology when revenue holds up?
Stable or rising revenue can coexist with weaker profit when Align earns less per case or incurs higher operating costs. The latest results already show revenue improving while gross profit and operating income declined, and management expects lower selling prices to remain a margin pressure.
How will restructuring affect Align Technology’s coming margins?
Management expects accelerated depreciation, restructuring and related charges to depress reported gross and operating margins. Adjusted expectations exclude much of that burden, so the durability of profitability is clearer when reported and adjusted outcomes are considered together.
Does Align Technology need heavy borrowing to support Invisalign and iTero investment?
Cash and short-term investments substantially exceed debt, while operating cash flow has remained positive across the reported periods. That gives Align room to fund research, product development and restructuring without making borrowing the central source of financial capacity.
What is the ALGN stock price today?
The last price recorded for Align Technology, Inc. (ALGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ALGN price target?
The analyst consensus price target for Align Technology, Inc. (ALGN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 77 figures on this page — 1 from SEC filings and earnings calls, 69 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold ALGN
Funds in our ETF coverage that list ALGN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Simplify Health Care ETF (PINK) | 8.11% | |
| Virtus KAR Mid-Cap ETF (KMID) | 3.74% | |
| Alger Russell Innovation ETF (INVN) | 2.71% |